ABSTRACTS (e-)POSTER PRESENTATIONS
A-137 COAGULATION FACTOR IX INHIBITOR DETERMINATION REVISITED: PRACTICAL EVALUATION OF THE ANTI-FIX BETHESDA ASSAY.
M. De Sloovere, K. Devreese
A-130 AMPKα1 PARTICIPATES IN THE REGULATION OF THROMBIN-INDUCED PHOSPHATIDYLSERINE EXPOSURE IN PLATELETS THROUGH ACETYL-COA CARBOXYLASE PHOSPHORYLATION
S. Lepropre, S. Kautbally, L. Bertrand, V.M. Darley-Usmar, G.R. Steinberg, B.E. Kemp, C. Beauloye, C. Oury, S. Horman
A-139 COMPARISON OF 4T-SCORE AND LABORATORY TESTS IN THE DIAGNOSIS OF HIT
L. Seaux, P. Meeus, E. Bailleul
A-138 COMPARISON OF ACTIVATED CLOTTING TIME MEASURED BY I-STAT, SONOCLOT AND ACTPLUS AND CORRELATION WITH ANTI-XA DURING CARDIOPULMONARY BYPASS PROCEDURES
S. Vandendriessche, F. De Somer, H. Laverge, K. Devreese
A-116 EVALUATION OF THE CLINICAL PERFORMANCE OF TWO AUTOMATED IMMUNOASSAYS IN THE DIAGNOSIS OF THROMBOTIC ANTIPHOSPHOLIPID SYNDROME
A. Vandevelde, L. Vanoverschelde, M. Luypaert, K. Devreese
A-141 INTERFERENCE OF CRP IN LUPUS ANTICOAGULANS TESTING: IS CRP THE ONLY CAUSE?
L. Seaux, P. Meeus, E. Bailleul
A-102 PERFORMANCE EVALUATION OF THE NEW POINT-OF-CARE COAGULATION ANALYZER XPRECIA STRIDE FOR MEASURING INR IN VKA-TREATED PATIENTS – COMPARISON WITH LOCAL LABORATORY AUTOMATED REFERENCE METHOD
P. Péters, C. Lecut, O. Bossu, A. Gothot
A-121 PHARMACOKINETIC RESULTS OF TWO STUDIES WITH A NEW FIBRINOGEN CONCENTRATE IN SUBJECTS WITH AFIBRINOGENAEMIA
A. Bellon, F. Bridey, W. Stevens, P. de Moerloose
A-126 PLATELET ACETYL-COA CARBOXYLASE PHOSPHORYLATION: A POTENTIAL MARKER FOR ATHEROTHROMBOTIC CORONARY ARTERY DISEASE
S. Kautbally, S. Lepropre, A. Lerigoleur, B. Gerber, J. Kefer, L. Bertrand, S. Horman, C. Beauloye
A-128 PREVALENCE OF HETEROZYGOUS TYPE 2N VON WILLEBRAND DISEASE MUTATIONS IN BELGIUM
J. Jongenotter, I. Vangenechten, K. Jochmans, C. Orlando, A. Gothot, K. Vandenbosch, A. Gadisseur
A-113 PREVENTABILITY OF SERIOUS ADVERSE DRUG REACTIONS RELATED TO THE USE OF DIRECT ORAL ANTICOAGULANTS: A PROSPECTIVE STUDY
A.-L. Sennesael, A.-S. Larock, B. Devalet, V. Mathieux, F. Verschuren, X. Muschart, O. Dalleur, J-M. Dogné, A. Spinewine
A-120 THE IMPORTANCE OF A LOW LIMIT OF DETECTION FOR COAGULATION FACTOR ASSAYS: FIX, AN EXAMPLE IN DAILY PRACTICE
M. De Sloovere, D. Arnoe, K. Devreese
A-133 ACQUIRED HAEMOPHILIA A
Y. Van der Beken, C. Orlando, K. Fostier, K. Jochmans
A-129 SUSTAINED INHIBITION OF ACETYL-COA CARBOXYLASE DECREASES PLATELET DENSE GRANULES SECRETION AND AGGREGATION
S. Lepropre, M. Octave, S. Kautbally, G. Muccioli, V.M. Darley-Usmar, L. Bertrand, C. Beauloye, S. Horman
A-132 PEAR1 PROMOTER METHYLATION IS ASSOCIATED WITH PLATELET AND WHITE BLOOD CELL PHENOTYPES IN THE MOLI-FAMILY COHORT
B. Izzi, F. Gianfagna, K. Cludts, C. Grippi, P. Verhamme, C. Cerletti, G. de Gaetano, M. Hoylaerts, L. Iacoviello
A-123 P2X1 ION CHANNEL IS CRITICAL FOR VASCULAR INTEGRITY IN INFLAMMATION
O. Wéra, C. Delierneux, L. Servais, A. Hego, C. Lecut, A. Nchimi, P. Lancellotti, C. Oury
A-134 ITPKB AS NEW PLATELET-ACTIVATION REGULATOR
P. Molina-Ortiz, C. Delierneux, M. Kuijpers, J.W.M. Heemskerk, C. Oury, S. Schurmans
A-117 GARP DEFICIENCY IN MURINE PLATELETS OR ENDOTHELIAL CELLS DOES NEITHER AFFECT HEMOSTASIS NOR THROMBOSIS
E. Vermeersch, W. Maes, S. De Meyer, K. VanHoorelbeke, D. Unutmaz, H. Fujii, H. Deckmyn, C. Tersteeg
A-135 CLUMPING FACTOR A, VON WILLEBRAND FACTOR-BINDING PROTEIN AND VON WILLEBRAND FACTOR TO THE VESSEL WALL
J. Claes, L. Liesenborghs, M. Peetermans, T.R. Veloso, D. Missiakas, O. Schneewind, S. Mancini, J.M. Entenza, M.F. Hoylaerts, R. Heying, P. Verhamme, T. Vanassche
A-112 ABSENCE OF PEAR1 DOES NOT AFFECT MURINE PLATELET FUNCTION
M. Criel, B. Izzi, C. Vandenbriele, L. Liesenborghs, S. van Kerckhoven, M. Lox, K. Cludts, E. A.V. Jones, T. Vanassche, P. Verhamme, M. Hoylaerts
A-115 ACQUIRED VON WILLEBRAND SYNDROME AFTER LEFT VENTRICULAR ASSIST DEVICE IMPLANTATION
S. Deconinck, E. Roose, N. VanDePutte, I. Pareyn, C. Tersteeg, L. Delrue, H. Deckmyn, S.F. De Meyer, M. Vanderheyden, K. VanHoorelbeke
A-103 VALIDATION OF A CHROMOGENIC ASSAY FOR FVIII: C AND FIX: C (CSA) MEASURING AND COMPARISON WITH A CHRONOMETRIC ASSAY (OSA)
C. Haeseleer, A. Demulder, P.-Q. Le, A. Hunanyan, A. Ferster, L. Rozen
ABSTRACTS ORAL PRESENTATIONS
A-124 THROMBUS COMPOSITION REFLECTS STROKE ETIOLOGY
F. Denorme, O. François, L. Desender, T. Andersson, H. Deckmyn, K. VanHoorelbeke, S.F. De Meyer
A-122 NEUTROPHIL EXTRACELLULAR TRAPS IN THROMBI FROM PATIENTS WITH ACUTE ISCHEMIC STROKE
E. Laridan, F. Denorme, L. Desender, O. François, T. Andersson, H. Deckmyn, K. VanHoorelbeke, S.F. De Meyer
A-108 N-ACETYLCYSTEINE IN PRECLINICAL ANIMAL MODELS OF THROMBOTIC THROMBOCYTOPENIC PURPURA
C. Tersteeg, J. Roodt, W. J Van Rensburg, C. Dekimpe, N. VanDePutte, I. Pareyn, A. Vandenbulcke, B. Plaimauer, S. Lamprecht, H. Deckmyn, J.A. Lopez, S. De Meyer, K. VanHoorelbeke
A-131 PLASMA ADAMTS13 ADOPTS A CLOSED CONFORMATION IN HEALTHY INDIVIDUALS
E. Roose, A.-S. Schelpe, L. Deforche, E. Broucke, D. David, H. Deckmyn, S.F. De Meyer, K. VanHoorelbeke
A-136 THE p.Arg498Cys MUTATION IN THE CYSTEINE RICH DOMAIN OF ADAMTS13 RESULTS IN A SECRETION DEFICIENCY
A.-S. Schelpe, C. Orlando, C. Geeroms, I. Pareyn, N. VanDePutte, H. Deckmyn, K. Jochmans, S.F. De Meyer, K. VanHoorelbeke
A-107 A CLINICALLY RELEVANT HYBRID ADENOVIRUS- TRANSPOSON VECTOR FOR GENE THERAPY FOR VON WILLEBRAND DISEASE
I. Portier, M. Solanki, H. Deckmyn, K. VanHoorelbeke, A. Ehrhardt, S.F. De Meyer
A-105 THE ROLE OF VON WILLEBRAND FACTOR IN A MALARIA-ASSOCIATED LUNG PATHOLOGY MODEL
S. Kraisin, S. Verhenne, T. Pham, N. VanDePutte, H. Deckmyn, K. VanHoorelbeke, P.E. Van Den Steen, S.F. De Meyer
A-109 UNRESTRAINED ENDOGENOUS PLASMIN ACTIVITY REVERSES ACUTE THROMBOTIC THROMBOCYTOPENIC PURPURA
C. Tersteeg, B. Joly, F. Denorme, L. Deforche, A. Gils, R. Lijnen, H. Deckmyn, P.J. Declerck, H. Rottensteiner, P. Coppo, A. Veyradier, S. De Meyer, C. Maas, K. VanHoorelbeke
A-111 CLOPIDOGREL PREVENTS COLITIS-ASSOCIATED CARCINOGENESIS IN MICE BY INHIBITING IMMUNOSUPPRESSIVE FUNCTION OF IMMATURE MYELOID CELLS
L. Servais, C. Delierneux, O. Wéra, A. Gothot, A. Nchimi, P. Lancellotti, C. Oury
A-140 STAPHYLOCOCCUS AUREUS AND STAPHYLOCOCCUS LUGDUNENSIS BIND VON WILLEBRAND FACTOR TO OVERCOME SHEAR STRESS AND CAUSE ENDOCARDITIS
L. Liesenborghs, J. Claes, M. Peetermans, M. Lox, R. Veloso, M. Criel, S. van Kerckhoven, K. Cludts, W. Peetermans, T. Vanassche, M. Hoylaerts, P. Verhamme
Top
